PE20142314A1 - Composiciones intranasales de dexmedetomidina y metodos de uso de ellas - Google Patents

Composiciones intranasales de dexmedetomidina y metodos de uso de ellas

Info

Publication number
PE20142314A1
PE20142314A1 PE2014000924A PE2014000924A PE20142314A1 PE 20142314 A1 PE20142314 A1 PE 20142314A1 PE 2014000924 A PE2014000924 A PE 2014000924A PE 2014000924 A PE2014000924 A PE 2014000924A PE 20142314 A1 PE20142314 A1 PE 20142314A1
Authority
PE
Peru
Prior art keywords
dexmedetomidine
methods
intranasal compositions
antimedetomidine
conservants
Prior art date
Application number
PE2014000924A
Other languages
English (en)
Inventor
Geraldine A Henwood
Randall J Mack
Jr John Joseph Koleng
Christopher T Sharr
Charles Alexander Freyer
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613351&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of PE20142314A1 publication Critical patent/PE20142314A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA AL COMPUESTO DEXMEDETOMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EL CUAL ES UTIL EN EL TRATAMIENTO DEL DOLOR. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A LA DEXMEDETOMIDINA Y PUEDE CONTENER ADEMAS, UN EXCIPIENTE PORTADOR, FOSFATO O CITRATO DE SODIO, UN AGENTE QUELANTE, UN AGENTE MEJORADOR DE LA VISCOSIDAD, UNO O MAS CONSERVANTES ANTIMICROBIANOS, UNO O MAS ANTIOXIDANTES
PE2014000924A 2011-12-11 2012-12-11 Composiciones intranasales de dexmedetomidina y metodos de uso de ellas PE20142314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161569255P 2011-12-11 2011-12-11

Publications (1)

Publication Number Publication Date
PE20142314A1 true PE20142314A1 (es) 2015-01-23

Family

ID=48613351

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000924A PE20142314A1 (es) 2011-12-11 2012-12-11 Composiciones intranasales de dexmedetomidina y metodos de uso de ellas

Country Status (21)

Country Link
US (2) US9795559B2 (es)
EP (2) EP3406247A1 (es)
JP (2) JP6268100B2 (es)
KR (1) KR102190009B1 (es)
CN (1) CN104470516A (es)
AU (2) AU2012352528B9 (es)
BR (1) BR112014019171A8 (es)
CA (1) CA2858721C (es)
CL (1) CL2014001515A1 (es)
CO (1) CO7000773A2 (es)
CR (1) CR20140318A (es)
DO (1) DOP2014000123A (es)
EC (1) ECSP14007644A (es)
HK (1) HK1203049A1 (es)
IL (1) IL232977B (es)
MX (1) MX367286B (es)
PE (1) PE20142314A1 (es)
PH (1) PH12014501273A1 (es)
RU (1) RU2692245C2 (es)
SG (2) SG11201403094TA (es)
WO (1) WO2013090278A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012031720A2 (pt) 2010-06-16 2016-12-06 Cargill Inc composições a base de amido para substituição por látex
KR102190009B1 (ko) * 2011-12-11 2020-12-15 바우닥스 바이오, 인코포레이티드 비강내 덱스메데토미딘(dexmedetomidine) 조성물 및 그 사용방법
DK3049059T3 (da) * 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
EP3054932B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
RU2648817C2 (ru) * 2013-10-07 2018-03-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для лечения абстинентных синдромов с использованием неседативных трансдермальных композиций на основе дексмедетомидина
EP3054930B1 (en) 2013-10-07 2020-12-02 Teikoku Pharma USA, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
EP4371554A2 (en) 2016-12-31 2024-05-22 BioXcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN114983980A (zh) * 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112107544A (zh) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用
KR20230136612A (ko) * 2021-01-04 2023-09-26 바이오엑셀 테라퓨틱스 인코포레이티드 덱스메데토미딘 치료 용법
CN115137699B (zh) * 2021-03-29 2024-05-03 四川普锐特药业有限公司 一种增效防腐的右美托咪定鼻喷剂
CN113876776A (zh) * 2021-11-04 2022-01-04 江苏大学附属医院 一种复方鼻喷镇痛药剂及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DK0560928T3 (da) 1990-12-05 1997-12-01 Gen Hospital Corp Anordninger til behandling af pulmonal vasokonstriktion og astma
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5713907A (en) 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
DE69733889T3 (de) 1996-05-29 2009-10-22 Delsitech Oy Lösliche oxide für biologische anwendungen
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
AU1319200A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6582457B2 (en) 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US20030022926A1 (en) 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
MY145817A (en) 2006-02-13 2012-04-30 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008003093A2 (en) 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN101057830A (zh) 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药***或组合物及其制备方法
CN101951886A (zh) * 2007-12-21 2011-01-19 先灵-普劳健康护理产品公司 增强羟甲唑啉的光稳定性
KR101859486B1 (ko) 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 설하용 덱스메데토미딘 조성물과 그의 사용 방법
SG177752A1 (en) 2009-07-27 2012-03-29 Trigemina Inc Methods for treatment of pain
RU2012133969A (ru) 2010-01-08 2014-02-20 Рекро Фарма, Инк. Локальные трансдермальные композиции дексмедетомидина и способы их применения
KR102190009B1 (ko) * 2011-12-11 2020-12-15 바우닥스 바이오, 인코포레이티드 비강내 덱스메데토미딘(dexmedetomidine) 조성물 및 그 사용방법

Also Published As

Publication number Publication date
IL232977A0 (en) 2014-07-31
US10682311B2 (en) 2020-06-16
RU2014128343A (ru) 2016-01-27
ECSP14007644A (es) 2015-11-30
MX367286B (es) 2019-08-13
WO2013090278A3 (en) 2014-12-24
CR20140318A (es) 2014-10-28
HK1203049A1 (en) 2015-10-16
US20130178465A1 (en) 2013-07-11
AU2018200591A1 (en) 2018-02-15
IL232977B (en) 2019-01-31
EP2787970A4 (en) 2015-10-28
JP2015513309A (ja) 2015-05-07
EP2787970B1 (en) 2018-04-11
DOP2014000123A (es) 2014-12-31
US9795559B2 (en) 2017-10-24
CO7000773A2 (es) 2014-07-21
KR20140107329A (ko) 2014-09-04
US20180055764A1 (en) 2018-03-01
EP3406247A1 (en) 2018-11-28
MX2014006961A (es) 2014-09-22
SG10201604653TA (en) 2016-07-28
SG11201403094TA (en) 2014-10-30
WO2013090278A2 (en) 2013-06-20
AU2012352528B2 (en) 2017-10-26
BR112014019171A2 (es) 2017-06-20
NZ626999A (en) 2016-07-29
RU2692245C2 (ru) 2019-06-24
AU2018200591B2 (en) 2018-11-29
AU2012352528B9 (en) 2017-11-02
CA2858721A1 (en) 2013-06-20
CA2858721C (en) 2021-03-16
JP6505177B2 (ja) 2019-04-24
JP6268100B2 (ja) 2018-01-24
BR112014019171A8 (pt) 2017-07-11
JP2018030850A (ja) 2018-03-01
CL2014001515A1 (es) 2014-12-05
AU2012352528A1 (en) 2014-07-10
EP2787970A2 (en) 2014-10-15
PH12014501273A1 (en) 2014-09-08
CN104470516A (zh) 2015-03-25
KR102190009B1 (ko) 2020-12-15

Similar Documents

Publication Publication Date Title
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201490254A1 (ru) Комбинированное лечение гепатита с
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
PH12016502355A1 (en) Pharmaceutical composition
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
EA201490573A1 (ru) Соединение бензотиазолона
RU2013110517A (ru) Средство для профилактики или лечения неалкогольного стеатогепатита
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
CU20130004A7 (es) Agentes terapéuticos 976
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол
EA201591994A1 (ru) Цистеин или его производное для лечения атрофического гастрита
AR100920A1 (es) Composiciones antimicrobianas con agentes efervescentes, método

Legal Events

Date Code Title Description
FC Refusal